In last trading session, G1 Therapeutics Inc (NASDAQ:GTHX) saw 0.55 million shares changing hands with its beta currently measuring 1.68. Company’s recent per share price level of $4.55 trading at -$0.13 or -2.78% at ring of the bell on the day assigns it a market valuation of $237.51M. That closing price of GTHX’s stock is at a discount of -9.89% from its 52-week high price of $5.00 and is indicating a premium of 76.26% from its 52-week low price of $1.08. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.87 million shares which gives us an average trading volume of 1.39 million if we extend that period to 3-months.
G1 Therapeutics Inc (NASDAQ:GTHX) trade information
Upright in the red during last session for losing -2.78%, in the last five days GTHX remained trading in the red while hitting it’s week-highest on Tuesday, 04/09/24 when the stock touched $4.55 price level, adding 6.95% to its value on the day. G1 Therapeutics Inc’s shares saw a change of 49.18% in year-to-date performance and have moved -4.81% in past 5-day. G1 Therapeutics Inc (NASDAQ:GTHX) showed a performance of 31.50% in past 30-days. Number of shares sold short was 2.76 million shares which calculate 2.51 days to cover the short interests.
G1 Therapeutics Inc (GTHX) estimates and forecasts
Statistics highlight that G1 Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 288.89% of value to its shares in past 6 months, showing an annual growth rate of 31.18% while that of industry is 13.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 60.40% in the current quarter and calculating -242.90% decrease in the next quarter. This year revenue growth is estimated to fall -15.30% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $15.26 million for the same. And 5 analysts are in estimates of company making revenue of $16.41 million in the next quarter that will end on Jun 2024. Company posted $12.95 million and $42.39 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 17.90% while estimating it to be -61.30% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 18.38% during past 5 years.
GTHX Dividends
G1 Therapeutics Inc is more likely to be releasing its next quarterly report between May 01 and May 06 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
G1 Therapeutics Inc (NASDAQ:GTHX)’s Major holders
Insiders are in possession of 11.68% of company’s total shares while institution are holding 30.15 percent of that, with stock having share float percentage of 34.14%. Investors also watch the number of corporate investors in a company very closely, which is 30.15% institutions for G1 Therapeutics Inc that are currently holding shares of the company. Vanguard Group Inc is the top institutional holder at GTHX for having 1.98 million shares of worth $9.02 million. And as of Dec 30, 2023, it was holding 3.80% of the company’s outstanding shares.
The second largest institutional holder is Susquehanna International Group, LLP, which was holding about 1.58 million shares on Dec 30, 2023. The number of shares represents firm’s hold over 3.02% of outstanding shares, having a total worth of $7.18 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 30, 2023, the former fund manager was holding 1.3 million shares of worth $5.89 million or 2.48% of the total outstanding shares. The later fund manager was in possession of 0.61 million shares on Dec 30, 2023, making its stake of worth around $2.8 million in the company or a holder of 1.18% of company’s stock.
